<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">34205</article-id><article-id pub-id-type="doi">10.26442/20795696.2020.2.200128</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Contraception modes: increasing women’s commitment to modern combined oral contraceptives with the shortest possible hormone-free interval</article-title><trans-title-group xml:lang="ru"><trans-title>Режимы контрацепции: повышение приверженности женщин современным комбинированным оральным контрацептивам с максимально коротким безгормональным интервалом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8425-0020</contrib-id><contrib-id contrib-id-type="spin">1239-2937</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreeva</surname><given-names>Elena N.</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>Елена Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., дир. Института репродуктивной медицины, зав. отд-нием эндокринной гинекологии, проф. каф. эндокринологии, зам. дир; </p></bio><email>s1981k@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7177-0254</contrib-id><contrib-id contrib-id-type="spin">9413-5136</contrib-id><name-alternatives><name xml:lang="en"><surname>Sheremetyeva</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Шереметьева</surname><given-names>Екатерина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><email>s1981k@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Yevdokimov Moscow State University of Medicine and Dentistry</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-05-12" publication-format="electronic"><day>12</day><month>05</month><year>2020</year></pub-date><volume>22</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>46</fpage><lpage>50</lpage><history><date date-type="received" iso-8601-date="2020-05-28"><day>28</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-05-28"><day>28</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/34205">https://gynecology.orscience.ru/2079-5831/article/view/34205</self-uri><abstract xml:lang="en"><p>By definition, contraception is the prevention of pregnancy and infection from diseases by mechanical, chemical and other contraceptives and methods. According to World Health Organization (WHO) statistics, up to 40% of women of reproductive age still believe that their needs for family planning services are not met during counseling. When recommending contraception, it is important to consider: the characteristics of the potential consumer, the underlying risk of the disease, possible undesirable drug reactions of various drugs, the cost, availability and preferences of the woman herself. Women are often forced to abandon the use of a contraceptive method in connection with adverse events, for example, when using combined oral contraceptives (COCs), they may feel worse (headaches, mood lability, weight gain, swelling, decreased libido) in a hormone-free interval, especially with the reception mode 21/7. Lack of contraception can lead to an increased risk of an unwanted pregnancy. According to statistics in the Russian Federation in 2018, the absolute number of abortions amounted to 567 183, which, according to the UN classification, corresponds to the average level (level of abortion rate per 1000 women of childbearing age). According to clinical practice, there is a relationship between deterioration of well-being and the duration of the hormone-free interval. At the moment, in our country there is the only COC, which has a hormone-free interval of 2 days, containing bioidentical estrogen – estradiol valerate and dienogest. According to the Cochrane Library, COCs with a short hormone-free interval are most effective in relation to the clinical manifestations of the “estrogen withdrawal” syndrome. WHO calls on clinicians to raise women’s awareness of modern methods of contraception.</p></abstract><trans-abstract xml:lang="ru"><p>Согласно определению, контрацепция – это предотвращение беременности и заражения от болезней механическими, химическими и другими противозачаточными средствами и способами. По статистике Всемирной организации здравоохранения (ВОЗ) до 40% женщин репродуктивного возраста по-прежнему считают, что их потребности в услугах планирования семьи не удовлетворяются во время консультирования. Рекомендуя контрацепцию, важно учитывать: характеристики потенциального потребителя, базовый риск заболевания, возможные нежелательные лекарственные реакции различных препаратов, стоимость, доступность и предпочтения самой женщины. Женщины часто вынуждены отказаться от использования того или иного метода контрацепции в связи с нежелательными явлениями, например, при использовании комбинированных оральных контрацептивов (КОК) возможно ухудшение самочувствия (головные боли, лабильность настроения, увеличение массы тела, отечность, снижение либидо) в безгормональный интервал, особенно при режиме приема 21/7. Отсутствие контрацепции может привести к увеличению риска наступления нежелательной беременности. Согласно статистике, в Российской Федерации в 2018 г. абсолютное число абортов составило 567 183, что, согласно классификации Организации Объединенных Наций, соответствует среднему уровню (уровень частоты абортов на 1 тыс. женщин фертильного возраста). По данным клинической практики имеется зависимость между ухудшением самочувствия и длительностью безгормонального интервала при приеме КОК. В настоящий момент в нашей стране есть единственный КОК, у которого безгормональный интервал 2 дня, содержащий эстроген, идентичный натуральному – эстрадиола валерат и диеногест. Согласно данным Кокрейновской библиотеки КОК с коротким безгормональным интервалом максимально эффективны в отношении клинических проявлений синдрома «эстрогеновой абстиненции». ВОЗ призывает врачей-клиницистов повышать информированность женщин в отношении современных методов контрацепции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>combined oral contraceptive</kwd><kwd>hormone-free interval</kwd><kwd>migraine</kwd><kwd>dysmenorrhea</kwd><kwd>pregnancy</kwd><kwd>estradiol valerate</kwd><kwd>quality of life</kwd><kwd>psychological status</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>комбинированный оральный контрацептив</kwd><kwd>безгормональный интервал</kwd><kwd>мигрень</kwd><kwd>дисменорея</kwd><kwd>беременность</kwd><kwd>эстрадиола валерат</kwd><kwd>качество жизни</kwd><kwd>психологический статус</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Свод практических рекомендаций по применению средств контрацепции. 2-е изд. ВОЗ, Фонд ООН в области народонаселения, 2005. [Selected practice recommendations for contraceptive use. 2nd ed., World Health Organization, 2005. (in Russian).]</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Пекинская рабочая программа, 1995 г., п. 95. [Pekinskaia rabochaia programma, 1995 g., p. 95. (in Russian).]</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Денисов Б.П., Сакевич В.И. Применение контрацепции в России: по материалам выборочного обследования. Доказательная медицина и клиническая эпидемиология. 2009; 1. [Denisov B.P., Sakevich V.I. Primenenie kontratseptsii v Rossii: po materialam vyborochnogo obsledovaniia. Dokazatel’naia meditsina i klinicheskaia epidemiologiia. 2009; 1. (in Russian).]</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Александрова Г.А., Голубев Н.А., Тюрина Е.М. и др. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. Сборник. М., 2019. [Aleksandrova G.A., Golubev N.A., Tiurina E.M., et al. Osnovnye pokazateli zdorov’ia materi i rebenka, deiatel’nost’ sluzhby okhrany detstva i rodovspomozheniia v Rossiiskoi Federatsii. Sbornik. M., 2019. (in Russian).]</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Токова З.З., Прилепская В.Н., Гата А.С., Куземин А.А. Статистика современных методов контрацепции в федеральных округах России. Гинекология. 2016; 18 (4): 68–71. [Tokova Z.Z., Prilepskaya V.N., Gata A.S., Kuzemin A.A. Special statistics of the modern methods of contraception in the federal districs of Russian Federation. Gynecology. 2016; 18 (4): 68–71. (in Russian).]</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Egarter C, Frey Tirri B, Bitzer J et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013; 13: 9. DOI: 10.1186/1472-6874-13-9</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Alkema L, Kantorova V, Menozzi C, Biddlecom A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet 2013; 381: 1642-52. DOI: 10.1016/S0140-6736(12)62204-1</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>https://www.gazeta.ru/science/2013/03/15_a_5057773.shtml</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Медицинские критерии приемлемости для использования методов контрацепции. 5-е изд. Женева, ВОЗ, 2015. [Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015 (in Russian).]</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Приказ Министерства здравоохранения РФ от 1 ноября 2012 г. №572н «Об утверждении Порядка оказания медицинской помощи по профилю “акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)”» [Prikaz Ministerstva zdravookhraneniia RF ot 1 noiabria 2012 g. №572n «Ob utverzhdenii Poriadka okazaniia meditsinskoi pomoshchi po profiliu “akusherstvo i ginekologiia (za iskliucheniem ispol’zovaniia vspomogatel’nykh reproduktivnykh tekhnologii)” (in Russian).]</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Дикке Г.Б., Ерофеева Л.В. Контрацепция в современной России: применение и информированность. Популяционное исследование. Акушерство и гинекология. 2016; 2: 108–13. http://dx.doi.org/10.18565/aig.2016.2.108-113 [Dikke G.B., Erofeeva L.V. Kontratseptsiia v sovremennoi Rossii: primenenie i informirovannost’. Populiatsionnoe issledovanie. Akusherstvo i ginekologiia. 2016; 2: 108–13. http://dx.doi.org/10.18565/aig.2016.2.108-113 (in Russian).]</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Прилепская В.Н. Руководство по контрацепции. 4-изд., доп. М.: МЕДпресс-информ, 2017. [Prilepskaia V.N. Rukovodstvo po kontratseptsii. 4-izd., dop. M.: MEDpress-inform, 2017 (in Russian).]</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sexual &amp; Reproductive Health 2018. DOI: 10.1136/bmjsrh-2017-200036</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dinger J. Comparative effectiveness of combined oral contraceptives in adolescents. J Fam Plann Reprod Health Care 2011; 37: 118. DOI: 10.1136/jfprhc.2011.0092</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Smith SK, Kirkman RJ, Arce BB et al. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Contraception 1986; 34: 513–22. DOI: 10.1016/0010-7824(86)90060-0</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zapata LB, Steenland MW, Brahmi D et al. Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review. Contraception 2013; 87: 685–700. DOI: 10.1016/j.contraception.2012.08.035</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Baerwald A, Olatunbosun O, Pierson R. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004; 70: 371–7. DOI: 10.1016/j.contraception.2004.05.006</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Dusterberg B, Nishino Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas 1982; 4: 315–24. 3.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women’s self-described reasons for missed pills. J Midwifery Women’s Health 2005; 50: 380–5. DOI: 10.1016/j.jmwh.2005.01.011</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6. DOI: 10.1016/s0029-7844(99)00524-4</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006; 74: 359–66. DOI: 10.1016/j.contraception.2006.06.003</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Nappi RE, Lobo Abascal P, Hsieh J, Micheletti MC. Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval. Int J Womens Health 2017; 9: 739–47. DOI: 10.2147/IJWH.S142078</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Bitzer J. Hormone withdrawal-associated symptoms: overlooked and under-explored. Gynecol Endocrinol 2013; 29 (6): 530–5. DOI: 10.3109/09513590.2012.760194</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Baerwald AR, Pierson RA. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can 2004; 26: 19–24.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sullivan H, Furniss H, Spona J et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72:115–20.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Klipping C, Duijkers I, Trummer D et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16–25.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Spona J, Elstein M, Feichtinger W et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71–7.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Legro RS, Pauli JG, Kunselman AR et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008;93: 420–9.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Zeun S et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009; 14: 221–32.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Fruzzetti F et al. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012; 28: 400–8.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Endrikat J, Blode H, Gerlinger C et al. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel. Eur J Contracept Reprod Health Care 2002; 7: 79–90.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sexual &amp; Reproductive Health 2018. DOI: 10.1136/bmjsrh-2017-200036</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Machado RB, Pereira AP, Coelho GP et al. Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception 2010; 81 (3): 202–8. DOI: 10.1016/j.contraception.2009.09.006</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Merki-Feld GS et al. Temporal relations in hormone-withdrawal migraines and impact on prevention- a diary-based pilot study in combined hormonal contraceptive users. J Headache Pain 2017; 18 (1): 91. DOI: 10.1186/s10194-017-0801-7</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Cupini LM, Matteis M, Troisi E et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995; 15: 140–4.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Sacco S, Merki-Feld GS et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain 2018; 19 (1): 76. DOI: 10.1186/s10194-018-0896-5</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>De Icco R et al. Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. J Headache Pain 2016; 17 (1): 70. DOI: 10.1186/s10194-016-0661-6</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Macìas G, Merki-Feld GS, Parke S et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol 2013; 33 (6): 591–6. DOI: 10.3109/01443615.2013.800851</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Nappi RE, Terreno E, Sances G et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception 2013; 88 (3): 369–75. DOI: 10.1016/j.contraception.2013.02.001.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Graziottin A, Serafini A. Perimenstrual asthma: from pathophysiology to treatment strategies. Multidiscip Respir Med 2016; 11: 30. DOI: 10.1186/s40248-016-0065-0</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Микаелян С.Т. Половые гормоны и бронхиальная астма у женщин. Успехи современного естествознания. 2007; 6: 76–8. [Mikaelian S.T. Polovye gormony i bronkhial’naia astma u zhenshchin. Uspekhi sovremennogo estestvoznaniia. 2007; 6: 76–8 (in Russian).]</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Овчаренко С.И., Капустина В.А. Особенности хронической обструктивной болезни легких у женщин. Consilium Medicum. 2009; 3: 5–13. [Ovcharenko S.I., Kapustina V.A. Osobennosti khronicheskoi obstruktivnoi bolezni legkikh u zhenshchin. Consilium Medicum. 2009; 3: 5–13 (in Russian).]</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Андреева Е.Н., Шереметьева Е.В. Проблема женской сексуальности. Проблемы репродукции. 2019; 25 (3): 40–50. https://doi.org/10.17116/repro20192503140 [Andreeva E.N., Sheremet’eva E.V. Problema zhenskoi seksual’nosti. Problemy reproduktsii. 2019; 25 (3): 40–50. https://doi.org/10.17116/repro20192503140 (in Russian).]</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Borgelt LM, Martell CW. Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive. Clin Ther 2012; 34 (1): 37–55. DOI: 10.1016/j.clinthera.2011.11.006</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health 2016; 8: 477–87.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Jensen JT, Bitzer J, Nappi RE et al. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur J Contracept Reprod Health Care 2020; 25 (2): 98–105. DOI: 10.1080/13625187.2020.1731734</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–39.</mixed-citation></ref></ref-list></back></article>
